HeartSciences (HSCS) Q1 2027 earnings summary

Executive summary

• Focus shifted to MyoVista Insights™, a cloud-native ECG management platform, with phased enhancements, Epic Toolbox designation in March 2026, and first US commercial agreements signed; commercialization of the MyoVista wavECG device is deprioritized due to regulatory and market factors.

• Entered into a Merger Agreement with Fortitude Mining Holdings, a digital asset mining platform focused on Zcash, with closing subject to shareholder approval and other conditions, expected in the second half of 2026.

• MyoVista Insights expanded its patent portfolio to over 45 granted patents and launched a new corporate website.

• Signed two commercial agreements for MyoVista Insights™ in May 2026, but no significant revenue generated yet from the platform.

Financial highlights

• Revenue for the quarter ended July 31, 2026 was $2,000, unchanged from the prior year, with no meaningful revenue reported for fiscal Q1 2027.

• Net loss for the quarter was $3.2 million, compared to $2.1 million in the same quarter last year.

• Research and development expenses decreased 9% year-over-year to $0.9 million, while selling, general, and administrative expenses increased 132% to $2.0 million, mainly due to merger-related costs and stock compensation.

• Cash and cash equivalents declined to $29,906 as of July 31, 2026, from $1.7 million at the start of the quarter.

• Accumulated deficit reached $88.4 million as of July 31, 2026.

Outlook and guidance

• Additional funding is required to support working capital and continued development of MyoVista Insights™.

• The company’s ability to continue as a going concern is in doubt due to recurring losses, negative cash flows, and limited capital resources.

• Completion of the proposed merger is uncertain and failure to close would likely have a material adverse effect on business and stock price.

• Management expects significant commercial progress for MyoVista Insights in the coming year, focusing on execution and delivery.

• No probable timeline for commercialization of the MyoVista wavECG device due to regulatory and market factors.